Date: 2016-06-30
Type of information: Private placement
Company: Bionor Pharma (Norway)
Investors:
Amount:
Funding type: private placement
Planned used:
Others: * On June 30, 2016, Referring to stock exchange announcement as of 20 June 2016, the Board of Directors of Bionor Pharma ASA announced, that the contemplated private placement of up to about NOK 70 million will be postponed until the ongoing pre-sounding phase has been concluded and alternative strategic solutions have also been sufficiently investigated. * On June 20, 2016, Bionor Pharma announced that the Board contemplates to launch a private placement of up to about NOK 70 million to be conducted within the end of this month. Further details on exact timing and structure of this transaction will be disclosed when the result of a pre-sounding phase has been concluded.This announcement follows the stock exchange announcement as of 31 May 2016, in which it was disclosed that the Board had decided that the company's long-term funding initially would be covered by an equity offering to fund the company through the following 6-12 months.
Therapeutic area: Infectious diseases
